Evidence map›Paper›PMID 29734672›Full record

SynthesisInternational journal of molecular sciences2018

Meta-Analysis and Experimental Validation Identified FREM2 and SPRY1 as New Glioblastoma Marker Candidates.

Marko Vidak, Ivana Jovcevska, Neja Samec, Alja Zottel, Mirjana Liovic, Damjana Rozman, Saso Dzeroski, Peter Juvan, Radovan Komel

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. HighCancers · 2019
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Marko VidakFaculty of Medicine, Medical Centre for Molecular Biology, University of Ljubljana, Ljubljana SI-1000, Slovenia. marko.vidak@mf.uni-lj.si.
Ivana JovcevskaFaculty of Medicine, Medical Centre for Molecular Biology, University of Ljubljana, Ljubljana SI-1000, Slovenia. ivana.jovcevska@mf.uni-lj.si.
Neja SamecFaculty of Medicine, Medical Centre for Molecular Biology, University of Ljubljana, Ljubljana SI-1000, Slovenia. neja.samec@mf.uni-lj.si.
Alja ZottelFaculty of Medicine, Medical Centre for Molecular Biology, University of Ljubljana, Ljubljana SI-1000, Slovenia. alja.zottel@mf.uni-lj.si.
Mirjana LiovicFaculty of Medicine, Medical Centre for Molecular Biology, University of Ljubljana, Ljubljana SI-1000, Slovenia. mirjana.liovic@mf.uni-lj.si.
Damjana RozmanFaculty of Medicine, Centre for Functional Genomics and Bio-Chips, University of Ljubljana, Ljubljana SI-1000, Slovenia. damjana.rozman@mf.uni-lj.si.
Saso DzeroskiDepartment of Knowledge Technologies, Jozef Stefan Institute, Ljubljana SI-1000, Slovenia. saso.dzeroski@ijs.si.
Peter JuvanFaculty of Medicine, Centre for Functional Genomics and Bio-Chips, University of Ljubljana, Ljubljana SI-1000, Slovenia. peter.juvan@mf.uni-lj.si.
Radovan KomelFaculty of Medicine, Medical Centre for Molecular Biology, University of Ljubljana, Ljubljana SI-1000, Slovenia. radovan.komel@mf.uni-lj.si.
University of Ljubljana · SIJožef Stefan Institute · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GB) is the most aggressive brain malignancy. Although some potential glioblastoma biomarkers have already been identified, there is a lack of cell membrane-bound biomarkers capable of distinguishing brain tissue from glioblastoma and/or glioblastoma stem cells (GSC), which are responsible for the rapid post-operative tumor reoccurrence. In order to find new GB/GSC marker candidates that would be cell surface proteins (CSP), we have performed meta-analysis of genome-scale mRNA expression data from three data repositories (GEO, ArrayExpress and GLIOMASdb). The search yielded ten appropriate datasets, and three (GSE4290/GDS1962, GSE23806/GDS3885, and GLIOMASdb) were used for selection of new GB/GSC marker candidates, while the other seven (GSE4412/GDS1975, GSE4412/GDS1976, E-GEOD-52009, E-GEOD-68848, E-GEOD-16011, E-GEOD-4536, and E-GEOD-74571) were used for bioinformatic validation. The selection identified four new CSP-encoding candidate genes—

Indexed as

AstrocytesBiomarkers, TumorCell Line, TumorExtracellular Matrix ProteinsGene Expression Regulation, NeoplasticGlioblastomaHumansMembrane ProteinsNeoplastic Stem CellsPhosphoproteinsProteomicsBiomarkers, TumorExtracellular Matrix ProteinsFREM2 protein, humanMembrane ProteinsPhosphoproteinsSPRY1 protein, humanbiomarkerscell surfacedata repositoriesexperimental validationFREM2glioblastomaglioblastoma stem cellsmeta-analysisSPRY1

Identifiers

PMID29734672
PMCPMC5983642
OpenAlexW2802151882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.